NICE backs Amicus’ Galafold for Fabry disease
The National Institute for Health and Care Excellence is backing National Health Service use of Amicus Therapeutics’ Galafold for treating the rare genetic disorder Fabry disease.
Read More
Tag: miglastat
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
